Drug treatment of obsessive-compulsive disorder by Kellner, Michael
hile only a few decades ago “obsessive neurosis”
had been regarded as a psychiatric condition that was
mostly treatment-refractory, several effective therapeutic
strategies for obsessive-compulsive disorder (OCD)—both
psychotherapeutic drugs and behavioral psychotherapeu-
tic techniques—began to evolve during the last third of the
20th century. 
In terms of modern pharmacotherapy, the first hints of
the efficacy of clomipramine, a tricyclic antidepressant
(TCA), which inhibits serotonin reuptake, date back
about 40 years.
1-3 In the 1970s, research with more strin-
gent designs in this area began, and soon placebo-con-
trolled trials showed the antiobsessive and anticompul-
sive action of clomipramine.
4-6 Interestingly, specific
anti-OCD effects were even observed when comorbid
depression was rigorously excluded. Treatment of OCD
patients may require relatively high doses for an
extended period of time, which may be accounted for by
a greater delay of effect in the orbitofrontal cortex, which
is thought to be implicated in OCD.
7A possible role of
serotonergic neurotransmission in the pathophysiology
of OCD was surmised by the results of the studies with
clomipramine, by later numerous investigations showing
the therapeutic action of different selective serotonin
reuptake inhibitors (SSRIs) in OCD, and by additional
findings, such as the provocation of OCD symptoms by
the serotonergic agent m-chlorophenylpiperazine.
8-10
Interestingly, predominantly noradrenergic drugs, such as
the TCAs desipramine
11 and nortriptyline
4 were less
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Knowledge of pharmacotherapeutic treatment options
in obsessive-compulsive disorder (OCD) has grown con-
siderably over the past 40 years. Serotonergic antide-
pressants, such as selective serotonin reuptake inhibitors
(SSRIs) and clomipramine, are the established pharma-
cologic first-line treatment of OCD. Medium to large
dosages and acute treatment for at least 3 months are
recommended until efficacy is assessed. In case of signif-
icant improvement, maintenance treatment is necessary.
Unfortunately, about half of the patients do not respond
sufficiently to oral serotonergic antidepressants; aug-
mentation with atypical antipsychotics is an established
second-line drug treatment strategy. Alternatives include
intravenous serotonergic antidepressants and combina-
tion with or switch to cognitive behavioral psychother-
apy. Remarkably, a considerable proportion of OCD
patients still do not receive rational drug treatment.
Novel research approaches, such as preliminary treat-
ment studies with glutamatergic substances, and trials
with further drugs, as well as needed aspects of future
research, are reviewed. 
© 2010, LLS SAS Dialogues Clin Neurosci. 2010;12:187-197.
PAGES_11_AG_1009_BA.qxd:DCNS#45  9/06/10  10:27  Page 187effective than clomipramine. The additional importance
of dopamine
12,13 and glutamate dysfunction
14,15 in the
pathophysiology of OCD has been established, and led
to pharmacotherapeutic applications beyond serotoner-
gic drugs.
Notwithstanding the progress of pharmacotherapy of
OCD, even nowadays a high percentage of patients with
OCD obviously do not receive adequate drug treatment:
upon admission to a northwest European university psy-
chiatric centre, more than one third never had received
any pharmacotherapy, one in seven had received inap-
propriate drugs, and half of the patients had never been
treated with an adequate dose of a serotonin reuptake
inhibitor (SRI).
16 An interesting side aspect of pharma-
cotherapy of OCD is that patients with OCD show a
considerably lower placebo response than subjects with
other anxiety disorders, which is not caused by differen-
tial expectancy.
17 This phenomenon, and data about the
rarity of spontaneous remission of OCD in all age
groups,
18 add evidence for the necessity of administering
effective therapeutic approaches to try to reduce long-
term morbidity.
In this brief review, current pharmacotherapeutic treat-
ment options for OCD in adults will be highlighted,
beginning with established first-line treatments. Then,
special emphasis will be given on worthwhile, but still
preliminary, strategies for treatment-refractory patients.
Finally, a short perspective of potential future aspects of
pharmacotherapy of OCD will be discussed. 
First-line agents in OCD: 
SSRIs and clomipramine
SSRIs and the SRI clomipramine are recommended as
first-line agents for drug treatment of OCD due to the
convincing database from numerous published random-
ized controlled trials (RCTs), according to several meta-
analyses,
19 current expert guidelines, and consensus state-
ments.
20-24 Rather than citing the ample single and mostly
equivocal research papers, reference to some of the lat-
ter articles will primarily be given in this section.
The current guidelines of the World Federation of
Societies of Biological Psychiatry (WFSBP) for the phar-
macological treatment of OCD
24 grant the highest cate-
gory of evidence (“A”, ie, full evidence from several RCTs)
for the SSRIs escitalopram, fluvoxamine, fluoxetine, parox-
etine, and sertraline, as well as for the TCA clomipramine,
but not for any other drug. Because clomipramine is less
well tolerated than the SSRIs, it was given a recommen-
dation grade of 2 (moderate risk benefit ratio), while the
SSRIs received the highest recommendation grade 1
(good risk:benefit ratio). As for citalopram, only one pos-
itive double-blind, placebo-controlled study was published,
and only a recommendation grade of 3 (limited evidence
from controlled studies) was given. 
This WFSBP guideline mentions that usually lower
response rates are achieved in OCD in comparison with
other anxiety disorders, and that sometimes only partial
remission is achieved. As a rule, somewhat higher doses
are used for these drugs in OCD than for other anxiety
disorders, higher doses being associated with greater effi-
cacy in some, but not all, evaluations. In several long-
term and relapse-prevention studies, SRIs were shown
to be superior to placebo, pointing to the requirement of
long-term treatment of OCD. According to a systematic
review on all long-term, placebo-controlled trials with
SSRIs in OCD,
25 the likelihood of relapse during 24 to
52 weeks of treatment was significantly lower on an
SSRI than with placebo. Thus, successful treatment with
SSRIs should be maintained at the maximal effective
dose for at least 12 months.
An extensive display of the many acute treatment stud-
ies on SSRIs versus placebo, different doses of SSRIs,
SSRIs versus other SSRIs, clomipramine versus placebo,
SSRIs versus clomipramine, SSRIs versus placebo, or
clomipramine for continuation treatment and SSRIs vs
placebo or clomipramine for relapse-prevention treat-
ment can also be found in the guidelines on core inter-
ventions in the treatment of OCD of the National
Institute for Health and Clinical Excellence (NICE) of
the British Psychological Society and the Royal College
of Psychiatrists.
21 According to these guidelines, the ini-
tial pharmacological treatment in adults with OCD
should be one of the following SSRIs: fluoxetine, flu-
voxamine, paroxetine, sertraline, or citalopram. Of note,
studies on the efficacy of escitalopram in OCD were
published only later.
26
A current Cochrane review of placebo-controlled SSRI
trials in OCD, comprising 17 studies with 3097 partici-
pants, also showed efficacy for all SSRIs included (citalo-
pram, fluoxetine, fluvoxamine, paroxetine, and sertra-
line).
27The authors detected no statistical differences in
short-term therapeutic action among the individual
SSRIs. For a reliable estimation of potential differences
in tolerability between the different SSRIs, further study
is needed.
Clinical research
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to serotonergic antidepressants
Despite the proven efficacy of SSRIs and clomipramine
in OCD, as shown above, about 40% to 60% of patients
show no or just partial symptom improvement to a
treatment with a first-line drug.
28 Therefore, the search
for effective second-line treatment strategies in drug-
refractory OCD patients is of great clinical importance.
However, most of the following options still stand on
considerably weaker empirical grounds than the well-
established first–line recommendations described
above.
Modification of serotonergic drug therapy with first-
line agents
Intravenous clomipramine was shown to be more effec-
tive than oral clomipramine in two double-blind
placebo-controlled trials,
29,30 and thus was considered a
recommendation grade 3 strategy for treatment-resis-
tant OCD patients (limited evidence from controlled
studies).
24 Regarding citalopram, an open trial showed a
beneficial and relatively rapid response in OCD patients
resistant to previous oral therapy.
31 However, more
sophisticated studies are still needed. 
High-dose treatment with serotonergic drugs is another
strategy worth considering. Greater improvement with
higher vs lower doses of SSRI was reported using 250
to400 mg/d vs 200 mg/d of sertraline
32 and with escitalo-
pram after an increase of dose from 20 up to 50 mg/d.
33
However, two recent studies with escitalopram contra-
dict the notion that a positive response requires higher
doses of treatment. A similar response after 24 weeks of
10 mg/d vs 20 mg/d was shown in a double-blind
placebo-controlled study.
26 In an open study, a superior
reduction in OCD symptoms was found with 30 mg/d vs
20 mg/d of escitalopram, which, however, disappeared
when initial comorbid depression and anxiety were con-
sidered as analysis covariates.
34
Whether switching from one first-line drug to another
may be advisable, is still an unresolved issue. In one open
study, switching from one SSRI to another resulted in a
lower response rate (0% to 20%) than switching from
one SSRI to clomipramine (33% to 40%).
35 Although
meta-analyses have reported a larger treatment effect of
oral clomipramine than for SSRIs, head-to-head com-
parator studies do not support this evidence.
36
Some open-label studies suggest that combined treat-
ment of clomipramine and an SSRI is effective and well
tolerated. Positive results have been reported with long-
term augmentation with citalopram (up to 60 mg/d) in
20 treatment-resistent OCD patients on clomipramine.
37
In smaller samples, encouraging data have also been
reported with the combination of clomipramine with flu-
oxetine
38 or with sertraline.
39
Augmentation with antipsychotics
The combination of the antipsychotics risperidone,
haloperidol, olanzapine, or quetiapine with an SSRI was
shown to be more effective than SSRI monotherapy in
treatment-resistant cases and is recommended (grade 3,
ie, limited evidence from controlled studies) by the
WFSBP guidelines.
24 In most studies, response occurred
within 1 month of augmentation. After such treatment,
which should be initiated only after at least 3 months of
maximally tolerated therapy of an SSRI, about one third
of treatment-refractory OCD patients show a clinically
meaningful amelioration. 
In several meta-analyses positive acute effects of
antipsychotic augmentation were demonstrated.
40-42
Despite their recommendation, the WFSBP guideline
24
mentions that evidence for the efficacy of quetiapine
and olanzapine was still inconclusive according to
respective systematic review.
40 Further meta-analyses
about quetiapine showed equivocal results.
43,44A recent
double-blind augmentation study with quetiapine in
severe OCD patients failed to show an effect of queti-
apine.
45 In contrast, superior effects of quetiapine ver-
sus ziprasidone as an adjunct to SSRI were found in
treatment-resistant OCD patients in a retrospective
study.
46 Interestingly, (primary!) addition of quetiapine
to citalopram was more effective than citalopram alone
in reducing OCD symptoms in a large double-blind
study in treatment-naïve or medication-free OCD
patients,
47 although extrapolation of these results to aug-
mentation studies sensu stricto may be problematic.
Regarding olanzapine, a single-blind study comparing
risperidone versus olanzapine augmentation of SSRIs
showed positive responses without differences between
the two treatment groups.
48The long-term effectiveness
of atypical antipsychotics in the augmentation of SSRIs
has so far not sufficiently been studied and was not sup-
ported in a trial using olanzapine, quetiapine, and
risperidone.
49
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candidates for augmentation therapies of serotonin
reuptake inhibitors according to various case reports and
open studies. In a 12-week, open-label, flexible-dose trial
of aripiprazole, significant improvement of OCD symp-
toms was demonstrated.
50 Some respective case reports
with aripiprazole had been published before.
51 Even as
monotherapy, a case series suggests that aripiprazole
holds promise for treating OCD.
52 Also for amisulpride
augmentation, an open study has shown promising
results.
53Augmentation with perospirone resulted in ben-
eficial effects in a case report.
54
Augmentation with or switch to cognitive-behavioral
psychotherapy
Preliminary evidence supports the usefulness of cogni-
tive-behavioral therapy (CBT) as a nonpharmacological
augmentation treatment. In a randomized controlled
trial in patients who were on a therapeutic dose of SSRI
for at least 12 weeks, and continued to display clinically
significant OCD symptoms, the augmentative effect of
exposure and ritual prevention versus stress manage-
ment training was compared; after 8 weeks significantly
more patients with exposure and response prevention
showed a decrease of symptom severity of at least 25%
and achieved minimal symptoms.
55 In a naturalistic set-
ting, the usefulness of CBT (including exposure and rit-
ual prevention) in nonresponders to at least one ade-
quate trial with a serotonergic antidepressant was
shown, while pharmacologic treatment underwent no
changes under the trial.
56 In patients responding to 3
months of drug treatment, but showing residual symp-
toms of OCD, a greater improvement of OCD symp-
toms after addition of behavior therapy for 6 months
versus continuation of drug treatment alone was shown,
and significantly more patients achieved remission.
57
However, no control condition for behavior therapy was
used.
Also, a switch to CBT should be considered. In a wait-
list-controlled open trial, patients with a history of an
inadequate response to multiple serotonin reuptake
medications in adequate doses were treated with 15 ses-
sions of outpatient CBT, incorporating exposure and rit-
ual prevention.
58 OCD symptoms decreased significantly
and gains were maintained over 6 months. Further stud-
ies with more elaborate designs are needed. Although a
meta-analysis of psychotherapy and pharmacotherapy
for OCD
59 found highest effect sizes for combined treat-
ment, no clear advantage for the combination of sero-
tonergic antidepressants and CBT was detected in the
individual controlled trials published so far.
60
Augmentation with or switch to other drugs
Numerous further drugs have been studied for augmen-
tation or in monotherapy for the treatment of OCD, but
so far, none of these approaches described below has
reached sufficient empirical evidence to become recom-
mended in treatment guidelines.
24 However, some of
these drugs seem promising for further study and may
be attempted in OCD patients, who were refractory to
treatments with superior current evidence.
Glutamatergic agents are among the most exciting new
candidates in the treatment of OCD.
14,15 In an open-label
augmentation trial with memantine, an N-methyl-D-
aspartate (NMDA) glutamate receptor antagonist, a
meaningful improvement of symptoms was seen in
nearly half of the patients, who had failed to respond to
treatment with an SSRI for at least 3 months.
61 Case
reports of refractory OCD patients successfully treated
with an augmentation of memantine were published pre-
viously.
62,63 Interestingly, adjunctive glycine (an NMDA
glutamate receptor agonist) was also tested in a small
double-blind placebo-controlled trial and approached
efficacy for treatment of OCD symptoms.
64 For the glu-
tamate-modulating agent riluzole, which was added to
existing psychopharmacotherapy in treatment-resistant
OCD patients, significant antiobsessional effects were
observed in an open-label trial.
65 Also, amantadine
(another NMDA antagonist) could be a useful drug for
the treatment of OCD according to preclinical findings,
66
but human studies are so far missing. Augmentation with
topiramate, among other actions an α-amino-3-hydroxyl-
5-methyl-4-isoxazole-propionate (AMPA) glutamate
receptor antagonist, in treatment-resistant OCD patients
may be beneficial.
67,68 Respective double-blind studies
with topiramate are on their way (ClinicalTrials.gov
Identifiers: NCT00211744 and NCT00182520). Also for
pregabalin, which can indirectly inhibit glutamate release
via blockade of calcium channels, beneficial effects on
OCD symptoms in combination with serotonergic anti-
depressants have been reported in case reports.
69,70A dou-
ble-blind placebo-controlled study with pregablin in
SSRI-refractory OCD is being conducted
(ClinicalTrials.gov Identifier: NCT00994786). For aug-
Clinical research
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with glutamate modulator N-acetylcysteine, a marked
decrease of OCD symptoms was observed.
71A double-
blind study with this agent is currently recruiting patients
with OCD (ClinicalTrials.gov Identifier: NCT00539513).
Another interesting development with a glutamatergic
agent involves D-cycloserine, a partial agonist at the
NMDA receptor, which was found to facilitate fear
extinction learning in preclinical and human studies
when administered before or shortly after exposure to
fearful cues.
72 D-cycloserine augmentation of psy-
chotherapy with exposure and response prevention in
OCD has so far been investigated in three randomized,
double-blind, placebo-controlled studies. A study with
ten exposure sessions and drug intake 4 hours before
each session failed to support the use of D-cycloserine
(250 mg).
73 In contrast, significantly greater decreases in
obsession-related distress after four exposure sessions
under D-cycloserine (125 mg, given 2 hours before each
session) were reported.
74 However, the placebo group
tended to catch up after additional sessions. Both the
number of therapy dropouts and the number of sessions
needed to achieve “clinical milestones” were decreased
by active treatment. In another study, OCD patients
were reported to be significantly more improved under
D-cycloserine at mid-treatment (ten behavior therapy
sessions in total, dose of 100 mg 1 hour before each ses-
sion), but not at later time points.
75 Dosage and timing
of D-cycloserine as well as the number of combined
intervensions are critical parameters. So far, just a short-
term acceleration of response to exposure therapy under
D-cycloserine was shown, but no significant differences
in the further course due to floor effects of exposure
therapy.
Several antidepressants other than SSRIs or clomipramine
have been tested, as mentioned for noradrenergic tricyclics
above. For the alpha-2 receptor and serotonin (5-HT)2/3
receptor antagonist mirtazapine an open trial showed neg-
ative results.
76 However, in a double-blind discontinuation
period of 8 weeks (after an open trial) superiority of to
placebo was demonstrated.
77Addition of mirtazapine to
citalopram did not result in increased efficacy when com-
pared with addition of placebo, but was associated with an
accelerated onset of action in a single-blind study.
78
Preclinical experiments suggest that blockade of 5-HT2C
receptors may have an anticompulsive effect in OCD.
79
Therefore, agomelatine, a melatonin agonist and 5-HT2C
antagonist, would be worth studying in OCD as well, but
so far no reports have been published. The monoamino-
oxidase inhibitor phenelzine was shown to be as effective
as clomipramine in a double-blind trial in OCD patients,
80
while in another one it was no better than placebo.
81 A
double-blind study with St John’s wort (hypericum perfo-
ratum) failed to support efficacy for OCD.
82Trazodone, a
5-HT2 receptor antagonist and SRI, had shown sympto-
matic improvements in case series in clomipramine-resis-
tant OCD patients
83 and in augmentation of SSRIs.
84
However, a double-blind study indicated that trazodone
in monotherapy lacks substantial antiobsessive effects.
85
For selective serotonin-norepinephrine reuptake inhibitors
venlafaxine and duloxetine, reliable placebo-controlled tri-
als are still absent. In a double-blind comparison of ven-
lafaxine and paroxetine in primary OCD patients no sig-
nificant differences with regard to response or responder
rates were shown.
86 In a single-blind study, venlafaxine was
as efficacious as clomipramine in the acute treatment of
OCD.
87 In an open retrospective investigation in treat-
ment-resistant OCD beneficial effects of venlafaxine were
demonstrated.
88 According to case series and reports
switching from SSRI to duloxetine in treatment-resistant
OCD patients may be helpful.
89,90 For the selective nora-
drenaline reuptake inhibitor reboxetine, successful aug-
mentation of citalopram was reported in a single case.
91
For augmentation of SSRIs with pindolol, a 5-HT1A and
β-adrenergic antagonist, a double-blind placebo-con-
trolled trial found significant improvement of OCD
symptoms in treatment resistant patients,
92 while an open
trial only showed such effects after supplemental addi-
tion of tryptophan.
93 After double-blind primary addi-
tion of pindolol versus placebo to fluvoxamine, the
latency of antiobsessional response to the SSRI was not
shortened.
94A double-blind study of adjuvant buspirone,
a 5-HT1A partial agonist, in OCD patients, who had
shown to some extent an effect of clomipramine, did not
yield significant further clinical improvement.
95 For
lithium two double-blind augmentation studies have
been published that do not support its usefulness in
OCD. In fluvoxamine-refractory patients, a small though
statistically significant reduction of OCD symptoms was
reported, but the authors doubted the clinical meaning-
fulness of these findings.
96 A crossover study with adju-
vant lithium or thyroid hormone in clomipramine-
treated patients showed no significant change of OCD
symptoms after either treatment.
97
Benzodiazepine and opioid receptor ligands have been
tested in OCD. A double-blind combination study of
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effects during 12 weeks of treatment.
98 While in a dou-
ble-blind crossover study clonazepam in monotherapy
produced a significant decrement in OCD symptoms
during the first 3 weeks of treatment,
99 it was found to be
without effect in a 10-week double-blind placebo-con-
trolled trial.
100 A case of rapid remission of OCD with
tramadol was reported,
101 but so far no controlled stud-
ies have been published. In treatment resistant OCD
patients, who had failed two to six SRI trials, double-
blind addition of once-weekly morphine resulted in a
significant reduction of OCD symptoms at week two
versus placebo, while lorazepam as another control con-
dition was undistinguishable from placebo.
102
Augmentation with the opoid antagonist naltrexone did
not show efficacy for OCD symptoms in a double-blind
placebo-controlled study in SSRI or clomipramine
refractory patients.
103
For several other drugs preliminary interesting findings
mostly from short-term open studies or case reports
exist. Addition of gabapentin seems to shorten the time
of onset of fluoxetine’s antiobsessive effect.
104 Restarting
of previously untolerated serotonergic antidepressants
after valproate pretreatment was reported to lead to bet-
ter tolerance and reduction of OCD symptoms in a case
series.
105 Valproate monotherapy was successful in an
SRI-intolerant OCD patient.
106 The 5-HT3 receptor
antagonist ondansetrone may have promise both as
monotherapy
107 and as an augmentation strategy for
some OCD patients.
108Amelioration of refractory OCD
on treatment with clozapine was described in a few case
reports.
109-111Antiandrogenic treatment with cyproterone
acetate
112 and the long-acting gonadotropin-releasing
hormone analogue triptorelin
113 was reported to result in
considerable improvement of symptoms of OCD.
Marked decreases of symptoms were observed shortly
after single-dose exposures to the psychedelic drug psilo-
cybin in patients with OCD.
114 Nicotine treatment was
reported to display a favorable response, both in
monotherapy as well as for augmentation,
115-117 while
inositol augmentation of SSRIs led to a clinically signif-
icant response in some OCD patients in an open study
118;
in a small double-blind crossover study no significant
improvement by this second messenger precursor was
seen.
119Acute significant antiobsessional effects for a sin-
gle dose of dextroamphetamine were reported in a dou-
ble-blind crossover study in patients with severe OCD.
120
Improvement of OCD was seen in treatment-resistant
patients to serotonergic antidepressants after augmen-
tation with both dextroamphetamine and caffeine in a
double-blind study without placebo arm.
121
Future prospects
Despite the considerable current knowledge that has
been accumulated about evidence-based drug treatment
of adults with OCD, as given account of above, and as
summarized in Table I, several important clinical issues
are still unresolved and need further research. There is
still a paucity of long-term trials (especially for treat-
ment with SRIs for more than 1 year and for augmenta-
tion with antipsychotics). Furthermore, there are as yet
few switching studies, data on functional outcome para-
meters, combination studies of drug and cognitive
behavior therapy, and randomized controlled trials with
novel agents, such as glutamatergic drugs and further
atypical antipsychotics. 
Because of the relatively high rate of nonresponders,
prediction of response to different therapeutic
approaches in OCD and a further understanding of the
neurobiological underpinnings of successful treatment
of OCD is another important area of further research.
Clinical research
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First-line pharmacological treatment:
￿ Selective serotonin reuptake inhibitors (eg, escitalopram, fluvoxamine, fluoxetine, paroxetine or sertraline) or clomipramine
￿ Administration of medium to high doses
￿ Acute treatment of at least 3 months
￿ If efficacious, maintenance treatment of at least 1 year
Treatment options for patients refractory to first-line pharmacological treatment:
￿ Modification of first-line treatment (eg, intravenous clomipramine, further dose increase, switch to other or combination of first-line drugs)
￿ Augmentation with antipsychotics (eg, risperidone, haloperidol, quetiapine, olanzapine, or aripiprazole)
￿ Augmentation with (or switch to) cognitive-behavior therapy
￿ Trials with other drugs (please see text)
Table I. Algorithm for drug treatment of patients with obsessive-compulsive disorder.
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Currently, psychopathological or clinical parameters are
not very helpful in predicting response to pharma-
cotherapy, not to mention in providing us with differen-
tial therapeutic support regarding which drug or therapy
to choose. For treatment with SSRIs, severity and dura-
tion of OCD, psychosocial disability, earlier age at onset,
older age, comorbidity with depression and personality
disorder, absence of a positive family history for OCD,
and poor insight, as well as neurological soft signs, were
identified to predict poorer outcome.
122-129 Studies on the
impact of different symptom dimensions of OCD on
response to SSRIs have been equivocal, eg, while com-
pulsive hoarding was associated with poorer response to
different SSRIs in some studies,
130,131 hoarding symptoms
were reported to improve as much as other symptoms of
OCD after paroxetine.
132
Concerning neurobiological markers of response and
nonresponse to medication in OCD, preliminary results
using endophenotyping or brain imaging have been
reported. Functional polymorphisms in the serotonin sys-
tem and their impact on the response to serotonergic
antidepressants have yielded inconsistent results. No dif-
ferences on the total OCD score in fluvoxamine response
were detected in the genotype groups of the promoter
region of the serotonin transporter gene (5-HTTLPR),
133
as well as on treatment with different SRIs.
134 In contrast,
it was reported that a significant majority of responders
to paroxetine and venlafaxine carried the s/l genotype of
the 5-HTTLPR polymorphism; in OCD patients suc-
cessfully treated with paroxetine response was associated
with the G/G genotype of the 5-HT2A receptor poly-
morphism.
135 Using single photon emission computed
tomography (SPECT), higher pretreatment thalamus-
hypothalamus serotonin transporter availability in OCD
patients was found to significantly predicted better treat-
ment response to clomipramine.
136 In a positron emission
tomography (PET) study in OCD patients, local cerebral
metabolic rate for glucose was significantly decreased in
the head of the right caudate nucleus compared with pre-
treatment values in responders to fluoxetine; percentage
change in OCD symptoms correlated significantly with
the percent of right caudate/ipsilateral hemisphere
change.
137 In another PET study, higher pretreatment
regional glucose metabolism in the right caudate nucleus
was shown to significantly correlate with antiobsessional
response to paroxtine.
138 A significant correlation
between the amelioration of OCD on treatment with
serotonin reuptake inhibitors and the changes of the
dopamine transporter binding ratio in the right basal gan-
glia was found in a SPECT study, suggesting a role in the
improvement of OCD patients.
139 Distinct biological char-
acteristics were shown in OCD patients who respond to
SSRI (higher pretreatment glucose metabolism in the
right caudate nucleus) and in SSRI-refractory patients,
who benefit from adjunctive risperidone (higher pre-
treatment glucose metabolism in the right orbitofrontal
cortex and bilateral thalamus).
140 Using proton magnetic
resonance spectroscopy to measure N-acetyl-aspartate
(NAA), a putative marker of neuronal viability, signifi-
cantly lower NAA was observed in the anterior cingulate
only in OCD patients who responded to the combination
therapy of SSRI plus atypical antipsychotic.
141
Whether these exciting new developments will ulti-
mately further advance our understanding of the neu-
robiology and effective psychopharmacology of OCD,
and whether some of them will eventually enter clinical
practice to serve our OCD patients, still needs to be
established. ❏
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Tratamiento farmacológico del trastorno
obsesivo-compulsivo
En los últimos 40 años ha habido un importante
aumento del conocimiento de las opciones de far-
macoterapia para el trastorno obsesivo-compulsivo
(TOC). Los antidepresivos serotoninérgicos, como
los inhibidores selectivos de la recaptura de seroto-
nina (ISRS) y la clomipramina, se consideran los tra-
tamientos farmacológicos de primera línea en el
tratamiento del TOC. Se recomienda el empleo de
dosis intermedias o altas y un tratamiento agudo
de al menos tres meses antes de evaluar la eficacia.
En el caso de una mejoría significativa es necesario
el tratamiento de mantenimiento. Es lamentable
que cerca de la mitad de los pacientes no responda
suficientemente a antidepresivos serotoninérgicos
orales, por lo que la potenciación con antipsicóticos
atípicos es una estrategia de tratamiento farmaco-
lógico de segunda línea. Otras alternativas incluyen
los antidepresivos serotoninérgicos intravenosos y
la combinación con una psicoterapia cognitivo con-
ductual o un cambio a esta última. Es destacable
que un porcentaje considerable de pacientes con
TOC aun no recibe un tratamiento farmacológico
racional. Se revisan aproximaciones novedosas de
la investigación, como los estudios terapéuticos pre-
liminares con sustancias glutamatérgicas, y los ensa-
yos con otros fármacos, al igual que algunos aspec-
tos de la investigación futura.     
Traitement pharmacologique des troubles
obsessionnels compulsifs
Ces 40 dernières années ont vu s'améliorer de
manière importante la connaissance du traitement
pharmacologique du trouble obsessionnel compul-
sif (TOC).. Les antidépresseurs sérotoninergiques,
comme les inhibiteurs sélectifs de la recapture de la
sérotonine (ISRS) et la clomipramine, représentent le
traitement pharmacologique de première ligne
reconnu pour les TOC. Des posologies moyennes à
fortes sont nécessaires, avec une phase aiguë d'au
moins 3 mois pour obtenir des résultats et en cas
d’amélioration significative, un traitement d’entre-
tien est nécessaire. Malheureusement, environ la
moitié des patients ne répondent pas suffisamment
aux antidépresseurs sérotoninergiques oraux. La stra-
tégie thérapeutique de deuxième intention consiste
alors à additionner des antipsychotiques atypiques.
L’administration d’antidépresseurs sérotoninergiques
intraveineux et l’association ou le passage à la psy-
chothérapie cognitivocomportementale sont des
alternatives possibles. Étonnamment, un pourcen-
tage considérable de patients atteints de TOC ne
reçoit pas encore de traitement adapté. Nous analy-
sons dans cet article les nouvelles démarches concer-
nant la recherche, comme les études thérapeutiques
préliminaires avec des substances glutamatergiques,
les essais avec d’autres médicaments ainsi que cer-
taines perspectives nécessaires à la recherche future.
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